We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Harrow Health, Inc. an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amount of 8.625% senior notes due 2026 (the "Notes")
Harrow Health has filed a Form 8-K with the Securities and Exchange Commission containing a corporate presentation for its subsidiary, Mayfield Pharmaceuticals.